Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-A1811 vs TCbHP as Neoadjuvant Therapy in Early-stage or Locally Advanced HER2-positive Breast Cancer
NCT07196774Phase 3Active, not recruiting
- Sponsor
- Hengrui
- Start
- Oct 2025
- Primary completion
- Dec 2027
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of trastuzumab rezetecan in breast cancer, sponsored by Hengrui. Started Oct 2025; status: active, not recruiting.
02
Drugs
trastuzumab rezetecan
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT07196774.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07196774.